Tycoon Group Holdings Limited (HK:3390)
:3390
Want to see HK:3390 full AI Analyst Report?
Top Page
Tycoon Group Holdings Limited
(3390)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$0.25
▼(-15.17% Downside)
Action:Reiterated
Date:04/19/26
The score is driven primarily by improving fundamentals (2025 revenue rebound and return to positive operating/free cash flow) but capped by very thin margins and high year-to-year volatility in profitability and cash flows. Technicals add pressure due to a weak trend setup (below key moving averages and negative MACD), while valuation is only moderately supportive with a mid-range P/E and no dividend yield data.
Positive Factors
Revenue and cash flow recovery
A 15.3% revenue rebound in 2025 with operating and free cash flow turning positive (~97M/~96M) indicates the business regained demand traction and restored internal cash generation. Durable positive cash flow strengthens liquidity, funds working capital, and reduces reliance on external financing over the medium term.
Negative Factors
Thin and declining margins
Materially compressed margins—declining gross margin and single-digit operating/net margins—constrain the company's ability to generate sustainable profits from revenue. Low margin structure reduces buffer against cost shocks, limits reinvestment capacity, and makes earnings sensitive to procurement or pricing pressure over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and cash flow recovery
A 15.3% revenue rebound in 2025 with operating and free cash flow turning positive (~97M/~96M) indicates the business regained demand traction and restored internal cash generation. Durable positive cash flow strengthens liquidity, funds working capital, and reduces reliance on external financing over the medium term.
Read all positive factors
Tycoon Group Holdings Limited (3390) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$214.56M
Dividend Yield28%
Average Volume (3M)1.30M
Price to Earnings (P/E)13.7
Beta (1Y)0.03
Revenue Growth25.18%
EPS Growth245.83%
CountryHK
Employees258
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.02
Shares Outstanding894,000,000
10 Day Avg. Volume1,126,200
30 Day Avg. Volume1,299,466
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.44
Price to Sales (P/S)0.22
P/FCF Ratio2.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tycoon Group Holdings Limited Business Overview & Revenue Model
Company Description
Tycoon Group Holdings Limited functions as an investment holding enterprise, specializing in the worldwide distribution and retail of an extensive portfolio of health and wellness products. Its market presence extends across Hong Kong, Mainland Ch...
How the Company Makes Money
The company primarily makes money by purchasing healthcare products (notably pharmaceuticals and related medical/health products) from manufacturers and suppliers and selling them through its distribution network to downstream customers, earning r...
Tycoon Group Holdings Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
62
Positive
Cash Flow
54
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.10B | 876.04M | 1.20B | 1.19B | 888.87M |
| Gross Profit | 270.04M | 232.66M | 321.10M | 243.53M | 135.01M |
| EBITDA | 55.89M | 35.85M | 356.41M | 82.89M | 8.91M |
| Net Income | 15.67M | 3.24M | 297.32M | 43.75M | -18.82M |
Balance Sheet | |||||
| Total Assets | 1.17B | 1.01B | 988.95M | 1.01B | 881.46M |
| Cash, Cash Equivalents and Short-Term Investments | 70.34M | 34.02M | 39.10M | 74.60M | 71.63M |
| Total Debt | 428.05M | 330.98M | 206.16M | 341.60M | 239.08M |
| Total Liabilities | 625.03M | 516.61M | 445.40M | 718.96M | 620.20M |
| Stockholders Equity | 537.00M | 478.85M | 536.23M | 293.64M | 257.92M |
Cash Flow | |||||
| Free Cash Flow | 96.47M | -78.94M | 7.97M | -64.48M | -50.11M |
| Operating Cash Flow | 96.95M | -76.62M | 11.86M | -63.03M | -42.20M |
| Investing Cash Flow | -25.10M | 48.55M | 45.70M | -9.57M | -26.25M |
| Financing Cash Flow | -35.36M | 25.62M | -92.36M | 68.25M | 14.33M |
Tycoon Group Holdings Limited Technical Analysis
Negative
0.29
Price Trends
0.26
Negative
0.28
Negative
0.29
Negative
Market Momentum
>-0.01
Positive
37.72
Neutral
30.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3390, the sentiment is Negative. The current price of 0.29 is above the 20-day moving average (MA) of 0.25, above the 50-day MA of 0.26, and above the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 37.72 is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:3390.
Tycoon Group Holdings Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | HK$227.44M | 17.58 | 1.78% | 5.87% | -13.43% | -72.61% | |
54 Neutral | HK$214.56M | 13.71 | 2.98% | 28.00% | 25.18% | 245.83% | |
54 Neutral | HK$171.10M | -0.44 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$151.43M | -1.76 | -17.70% | ― | -38.20% | -108.24% | |
45 Neutral | HK$155.13M | -3.39 | -30.35% | ― | -12.03% | 6.24% | |
45 Neutral | HK$222.09M | -1.64 | -25.40% | 3.16% | -29.10% | -343.29% |
* Healthcare Sector Average
HK:3390
Tycoon Group Holdings Limited
0.24
-0.13
-35.14%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.06
-0.02
-28.92%
HK:1110
Kingworld Medicines Group Ltd.
0.36
-0.21
-36.84%
HK:1498
PuraPharm Corp. Ltd.
0.29
-0.19
-39.58%
HK:1518
New Century Healthcare Holding Co. Ltd.
0.46
-0.37
-45.18%
HK:2393
Yestar Healthcare Holdings Co Ltd
0.06
-0.05
-47.27%
Tycoon Group Holdings Limited Corporate Events
Tycoon Group Raises Connected Transaction Caps and Expands JBM Ties
Jun 12, 2026
Tycoon Group Holdings is revising the annual caps for certain continuing connected transactions with JBM Group after reviewing distribution agreements and concluding that transaction volumes are likely to exceed previous projections. The terms of ...
Tycoon Group Raises Caps on Connected Transactions With Talent Smart
Jun 12, 2026
Tycoon Group Holdings Limited plans to raise the annual caps on continuing connected transactions under its 2025 Master Sale and Purchase Agreement with Talent Smart Group after updated procurement plans showed actual transaction values are likely...
Tycoon Group Wins Strong Shareholder Backing for Capital Mandates at AGM
May 29, 2026
Tycoon Group Holdings Limited reported that all resolutions at its annual general meeting on 29 May 2026 were approved by shareholders via poll, with voting rights attached to the company’s entire issued share capital of 894 million shares a...
Tycoon Group Sets 2026 AGM to Renew Board, Auditor and Share Buyback Mandate
Apr 16, 2026
Tycoon Group Holdings Limited has convened its annual general meeting for 29 May 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements for the year ended 31 December 2025 and hear reports from th...
Tycoon Group Moves to Update Articles for Uncertificated Securities Regime
Apr 16, 2026
Tycoon Group Holdings plans to replace its existing third amended and restated articles of association with a new, fourth amended and restated version to align its corporate constitution with updated Hong Kong listing regulations. The changes are ...
Tycoon Group Profit Surges on 25% Revenue Growth in 2025
Mar 31, 2026
Tycoon Group Holdings Limited reported a strong set of results for the year ended 31 December 2025, with revenue rising 25.2% year on year to HK$1,096.6 million as the group expanded sales of its healthcare and consumer products. Net profit more t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.